Pregnancy outcome in patients with neuromyelitis optica spectrum disorder treated with rituximab: A case-series study
Background: Neuromyelitis optica spectrum disorder (NMOSD) is a neuroinflammatory disorder with a tendency to affect the spinal cord and optic nerves. As NMOSDs have a predilection for women of reproductive age and adopt an aggressive course during pregnancy, appropriate treatment strategies before...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Babol University of Medical Sciences
2021-07-01
|
| Series: | Caspian Journal of Internal Medicine |
| Subjects: | |
| Online Access: | http://caspjim.com/article-1-2678-en.html |
| _version_ | 1831761249195524096 |
|---|---|
| author | Maral Seyed Ahadi Mohammad Ali Sahraian Vahid Shaygannejad Nassim Anjidani Seyed Ehsan Mohammadiani Nejad Nahid Beladi Moghadam Hormoz Ayromlou Gholam Ali Yousefi Pour Sepideh Yazdanbakhsh Mehrdad Jafari Abdorreza Naser Moghadasi |
| author_facet | Maral Seyed Ahadi Mohammad Ali Sahraian Vahid Shaygannejad Nassim Anjidani Seyed Ehsan Mohammadiani Nejad Nahid Beladi Moghadam Hormoz Ayromlou Gholam Ali Yousefi Pour Sepideh Yazdanbakhsh Mehrdad Jafari Abdorreza Naser Moghadasi |
| author_sort | Maral Seyed Ahadi |
| collection | DOAJ |
| description | Background: Neuromyelitis optica spectrum disorder (NMOSD) is a neuroinflammatory disorder with a tendency to affect the spinal cord and optic nerves. As NMOSDs have a predilection for women of reproductive age and adopt an aggressive course during pregnancy, appropriate treatment strategies before conception and during pregnancy should be well-considered.
Case Presentation: In this report, the pregnancy outcome of eight pregnancies following rituximab treatment was assessed, which led to 50% live births with mean birth weight of 2777.50 (SD: 545.92) grams. Two patients had abortions due to doctor’s recommendation. One pregnancy led to intrauterine fetal death (IUFD) due to nuchal cord. No spontaneous abortions were encountered. Two patients received rituximab during pregnancy. No major malformations or serious neonatal infections were encountered.
Conclusion: Rituximab should be administered by caution in NMOSD patients who want to be pregnant and the probable adverse effects of the drug should be discussed by patients. |
| first_indexed | 2024-12-22T04:45:23Z |
| format | Article |
| id | doaj.art-24ee294ab53547b99995c7fd3a37c070 |
| institution | Directory Open Access Journal |
| issn | 2008-6164 2008-6172 |
| language | English |
| last_indexed | 2024-12-22T04:45:23Z |
| publishDate | 2021-07-01 |
| publisher | Babol University of Medical Sciences |
| record_format | Article |
| series | Caspian Journal of Internal Medicine |
| spelling | doaj.art-24ee294ab53547b99995c7fd3a37c0702022-12-21T18:38:37ZengBabol University of Medical SciencesCaspian Journal of Internal Medicine2008-61642008-61722021-07-0112Supplement 2491494Pregnancy outcome in patients with neuromyelitis optica spectrum disorder treated with rituximab: A case-series studyMaral Seyed Ahadi0Mohammad Ali Sahraian1Vahid Shaygannejad2Nassim Anjidani3Seyed Ehsan Mohammadiani Nejad4Nahid Beladi Moghadam5Hormoz Ayromlou6Gholam Ali Yousefi Pour7Sepideh Yazdanbakhsh8Mehrdad Jafari9Abdorreza Naser Moghadasi10 Multiple Sclerosis Research Center, Neuroscience institute, Tehran University of Medical Sciences, Tehran, Iran Multiple Sclerosis Research Center; Neuroscience institute; Tehran University of Medical Sciences; Tehran; Iran Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran Medical Department, Orchid Pharmed Company, Tehran, Iran Department of Neurology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran Department of Neurology, Shahid Beheshti University of Medical Sciences, Tehran, Iran Department of Neurology, Faculty of Medicine, Tabriz University of Medical Sciences, Iran Department of Neurology, Shiraz University of Medical Sciences, Shiraz, Iran Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran Imam Khomeini Hospital complex, Tehran University of Medical Sciences, Tehran, Iran Multiple Sclerosis Research Center, Neuroscience institute, Tehran University of Medical Sciences, Tehran, Iran Background: Neuromyelitis optica spectrum disorder (NMOSD) is a neuroinflammatory disorder with a tendency to affect the spinal cord and optic nerves. As NMOSDs have a predilection for women of reproductive age and adopt an aggressive course during pregnancy, appropriate treatment strategies before conception and during pregnancy should be well-considered. Case Presentation: In this report, the pregnancy outcome of eight pregnancies following rituximab treatment was assessed, which led to 50% live births with mean birth weight of 2777.50 (SD: 545.92) grams. Two patients had abortions due to doctor’s recommendation. One pregnancy led to intrauterine fetal death (IUFD) due to nuchal cord. No spontaneous abortions were encountered. Two patients received rituximab during pregnancy. No major malformations or serious neonatal infections were encountered. Conclusion: Rituximab should be administered by caution in NMOSD patients who want to be pregnant and the probable adverse effects of the drug should be discussed by patients.http://caspjim.com/article-1-2678-en.htmlneuromyelitis optica spectrum disorderrituximabpregnancy |
| spellingShingle | Maral Seyed Ahadi Mohammad Ali Sahraian Vahid Shaygannejad Nassim Anjidani Seyed Ehsan Mohammadiani Nejad Nahid Beladi Moghadam Hormoz Ayromlou Gholam Ali Yousefi Pour Sepideh Yazdanbakhsh Mehrdad Jafari Abdorreza Naser Moghadasi Pregnancy outcome in patients with neuromyelitis optica spectrum disorder treated with rituximab: A case-series study Caspian Journal of Internal Medicine neuromyelitis optica spectrum disorder rituximab pregnancy |
| title | Pregnancy outcome in patients with neuromyelitis optica spectrum disorder treated with rituximab: A case-series study |
| title_full | Pregnancy outcome in patients with neuromyelitis optica spectrum disorder treated with rituximab: A case-series study |
| title_fullStr | Pregnancy outcome in patients with neuromyelitis optica spectrum disorder treated with rituximab: A case-series study |
| title_full_unstemmed | Pregnancy outcome in patients with neuromyelitis optica spectrum disorder treated with rituximab: A case-series study |
| title_short | Pregnancy outcome in patients with neuromyelitis optica spectrum disorder treated with rituximab: A case-series study |
| title_sort | pregnancy outcome in patients with neuromyelitis optica spectrum disorder treated with rituximab a case series study |
| topic | neuromyelitis optica spectrum disorder rituximab pregnancy |
| url | http://caspjim.com/article-1-2678-en.html |
| work_keys_str_mv | AT maralseyedahadi pregnancyoutcomeinpatientswithneuromyelitisopticaspectrumdisordertreatedwithrituximabacaseseriesstudy AT mohammadalisahraian pregnancyoutcomeinpatientswithneuromyelitisopticaspectrumdisordertreatedwithrituximabacaseseriesstudy AT vahidshaygannejad pregnancyoutcomeinpatientswithneuromyelitisopticaspectrumdisordertreatedwithrituximabacaseseriesstudy AT nassimanjidani pregnancyoutcomeinpatientswithneuromyelitisopticaspectrumdisordertreatedwithrituximabacaseseriesstudy AT seyedehsanmohammadianinejad pregnancyoutcomeinpatientswithneuromyelitisopticaspectrumdisordertreatedwithrituximabacaseseriesstudy AT nahidbeladimoghadam pregnancyoutcomeinpatientswithneuromyelitisopticaspectrumdisordertreatedwithrituximabacaseseriesstudy AT hormozayromlou pregnancyoutcomeinpatientswithneuromyelitisopticaspectrumdisordertreatedwithrituximabacaseseriesstudy AT gholamaliyousefipour pregnancyoutcomeinpatientswithneuromyelitisopticaspectrumdisordertreatedwithrituximabacaseseriesstudy AT sepidehyazdanbakhsh pregnancyoutcomeinpatientswithneuromyelitisopticaspectrumdisordertreatedwithrituximabacaseseriesstudy AT mehrdadjafari pregnancyoutcomeinpatientswithneuromyelitisopticaspectrumdisordertreatedwithrituximabacaseseriesstudy AT abdorrezanasermoghadasi pregnancyoutcomeinpatientswithneuromyelitisopticaspectrumdisordertreatedwithrituximabacaseseriesstudy |